Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314613 · ClinicalTrials.gov registry record · Phase 4
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00314613 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 30 participants.
The verdict
NCT00314613, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.
Interventions
- DRUG Antipsychotic/Risperidone Consta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314613
The ClinicalTrials.gov registry entry for NCT00314613 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antipsychotic/Risperidone Consta is the first listed.
NCT00314613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314613 about?
NCT00314613 is a clinical study titled "Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal". Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.
What is the current status of trial NCT00314613?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00314613?
The interventions under investigation include: Antipsychotic/Risperidone Consta (DRUG).
Who is sponsoring clinical trial NCT00314613?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.